Ligand id: 7395

Name: daratumumab

View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species

Bioactivity Comments
Daratumumab is reported to induce complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) in patient-derived multiple myeloma cells [2].
Peptide sequence analysis of the heavy chain variable region of daratumumab matches a sequence claimed in patent US7829673 [1], and is the heavy chain component of monoclonal −005 described therein.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Affinity Units Concentration range (M) Reference
CD38 Hs Antibody Antagonist 8.2 pKd - 1
pKd 8.2 (Kd 6.06x10-9 M) [1]